Delayed Cord Clamping at Term Cesarean

May 20, 2019 updated by: Columbia University

Maternal Blood Loss With Delayed Cord Clamping During Cesarean Delivery at Term

The purpose of this research study is to find out how delaying cutting the umbilical cord until one minute after delivery of the baby during a cesarean impacts the amount of blood the mother loses during surgery. The study will also examine the benefits to the newborn from delayed cord clamping during cesarean.

Study Overview

Detailed Description

After delivery of a baby, the umbilical cord is cut to separate the baby from the placenta and the mother. The best time to cut the umbilical cord of full term babies is unknown. Traditionally, the umbilical cord is cut immediately at birth. There is however, continued blood flow from the placenta to the baby after delivery and so there may be a benefit to the baby from waiting to cut the cord until one minute after delivery. Studies show that delaying cutting the cord until at least one minute after delivery increases a full term baby's blood count in first two days of life and increases the baby's iron levels. The impact of delaying cutting the umbilical cord on a mother's health is not fully known. Delaying cutting the cord has minimal impact on the mother's health when the baby is delivered vaginally, but it is not known how delaying cutting the cord impacts the mother's health (and specifically the amount of blood a mother loses at delivery) when the baby is delivered by cesarean.

Study Type

Interventional

Enrollment (Actual)

113

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • New York, New York, United States, 10032
        • Columbia University Irving Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Singleton gestation
  • Scheduled cesarean delivery at term (>=37 weeks)

Exclusion Criteria:

  • Placenta previa
  • Placenta abruption
  • Intrauterine growth restriction with abnormal Dopplers
  • Fetal anomalies
  • Known fetal anemia
  • Planned cord blood banking
  • Preeclampsia
  • Significant maternal anemia (Hgb <=7)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
OTHER: Immediate cord clamping
Umbilical cord clamped within 15 seconds of delivery of baby
The umbilical cord will be clamped and cut after delivery, with timing as specified in each arm
EXPERIMENTAL: Delayed cord clamping
Umbilical cord clamped 60 seconds after delivery of baby
The umbilical cord will be clamped and cut after delivery, with timing as specified in each arm

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maternal change in hemoglobin on post-operative day #1
Time Frame: Baseline to postoperative day #1 (range 1-4 days)
Difference in hemoglobin between routine pre-op CBC and a postpartum CBC collected on postoperative day #1, by venipuncture
Baseline to postoperative day #1 (range 1-4 days)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postpartum hemorrhage
Time Frame: From day of surgery to postpartum discharge (average 3-4 days)
Incidence of postpartum hemorrhage, defined as EBL >1000cc
From day of surgery to postpartum discharge (average 3-4 days)
Estimated blood loss
Time Frame: Day of surgery
Estimated blood loss at cesarean delivery, based on estimation provider team
Day of surgery
Need for Need for additional uterotonics
Time Frame: Day of surgery
Administration of uterotonics (beyond standard pitocin) during cesarean
Day of surgery
Maternal blood transfusion
Time Frame: From day of surgery to postpartum discharge (average 3-4 days)
Transfusion of blood products during or after delivery
From day of surgery to postpartum discharge (average 3-4 days)
Venous cord blood Hgb/Hct
Time Frame: Day of delivery
Obtained from cord blood sample
Day of delivery
Neonatal Hgb/Hct
Time Frame: Day 0-2 of life
Obtained from neonatal heel stick
Day 0-2 of life
APGAR scores
Time Frame: Day of delivery
Assigned at delivery
Day of delivery
Need for phototherapy for jaundice
Time Frame: From birth to hospital discharge (average 3-4 days)
Any use of phototherapy
From birth to hospital discharge (average 3-4 days)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Cynthia Gyamfi-Bannerman, MD, Columbia University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

September 18, 2017

Primary Completion (ACTUAL)

March 30, 2018

Study Completion (ACTUAL)

March 31, 2018

Study Registration Dates

First Submitted

May 9, 2017

First Submitted That Met QC Criteria

May 10, 2017

First Posted (ACTUAL)

May 12, 2017

Study Record Updates

Last Update Posted (ACTUAL)

May 22, 2019

Last Update Submitted That Met QC Criteria

May 20, 2019

Last Verified

May 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AAAR2937

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cesarean Delivery

Clinical Trials on Umbilical cord clamping

3
Subscribe